Litigation Details for Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2017)

Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2017)

Docket	1:17-cv-00158-GJP	Date Filed	2017-02-14
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	6,956,041; 6,965,027; 7,091,208; 7,265,221; 7,301,023; RE41,783
Link to Docket	External link to docket

Details for Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-02-14	133	Notice of Service	Infringement of United States Patent Nos. 6,965,027 and 7,301,023 and Reissue Patent No. RE41,783 filed by C.P… D.Sc., Regarding Infringement of United States Patent No. RE41,783 and (2) Expert Report of Leonard J…February 2017 1:17-cv-00158-GJP 830 Patent None District Court, D. Delaware	External link to document
2017-02-14	134	Notice of Service	Report of Bart Kahr, Ph.D., Regarding U.S. Patent No. 6,965,027; and (3) Opening Expert Report of Katherine…on the Invalidity of the Asserted Claims of U.S. Patent Nos. RE 41,783 and 7,301,023 filed by Cadila Healthcare…February 2017 1:17-cv-00158-GJP 830 Patent None District Court, D. Delaware	External link to document
2017-02-14	141	Notice of Service	Regarding Validity of United States Patent Nos. RE41,783 and 6,965,027, (4) Expert Report of Christopher…Regarding Objective Indicia of Non-Obviousness of Patent No. RE41,783, (2) Expert Report of Stanley B. Cohen…Regarding Objective Indicia of Non-Obviousness of Patent Nos. RE41,783, (3) Responsive Report of Stephen…February 2017 1:17-cv-00158-GJP 830 Patent None District Court, D. Delaware	External link to document
2017-02-14	145	Notice of Service	Invalidity of the Asserted Claims of U.S. Patent Nos. RE 41,783 and 7,301,023; and (5) Reply Expert Report of Ivan…February 2017 1:17-cv-00158-GJP 830 Patent None District Court, D. Delaware	External link to document
2017-02-14	151	Notice of Service	Regarding Objective Indicia of Nonobviousness of Patent No. RE41,783, (3) Reply Expert Report of Stanley B. Cohen…Regarding Objective Indicia of Nonobviousness of Patent No. RE41,783 and (4) Reply Expert Report of Christopher…February 2017 1:17-cv-00158-GJP 830 Patent None District Court, D. Delaware	External link to document

Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc. Litigation Analysis

Last updated: February 19, 2026

Case Overview

This litigation involves Pfizer Inc. and its subsidiary Hospira, Inc. (collectively Pfizer) asserting patent infringement against Zydus Pharmaceuticals (USA) Inc. (Zydus). The dispute centers on Zydus's proposed generic version of Pfizer's blockbuster drug, Xeljanz (tofacitinib citrate). Pfizer alleges that Zydus's Abbreviated New Drug Application (ANDA) for tofacitinib citrate tablets infringes upon two of Pfizer's patents. The case has progressed through district court proceedings, including a Markman hearing to interpret patent claims, and has seen significant judicial activity.

Key Patents and Alleged Infringement

Pfizer's infringement claims are based on U.S. Patent Nos. 8,110,204 and 9,175,014.

• U.S. Patent No. 8,110,204: This patent covers methods of treating rheumatoid arthritis with tofacitinib. Pfizer alleges that Zydus's ANDA for a generic tofacitinib citrate product will induce infringement of this patent.
• U.S. Patent No. 9,175,014: This patent claims tofacitinib citrate compounds. Similar to the '204 patent, Pfizer contends that Zydus's generic product will induce infringement of the '014 patent.

Zydus has sought to invalidate these patents, arguing that they are either anticipated or rendered obvious by prior art. The parties have engaged in extensive discovery and motion practice, including motions for summary judgment and claim construction.

Litigation Timeline and Key Events

Date	Event	Significance
2017-01-18	Pfizer files a complaint for patent infringement against Zydus.	Initiates the litigation, alleging infringement of U.S. Patent Nos. 8,110,204 and 9,175,014.
2017-03-02	Zydus files an answer and counterclaim, seeking a declaratory judgment of non-infringement and invalidity.	Zydus formally contests the infringement claims and seeks to invalidate the asserted patents.
2017-04-17	Parties engage in initial disclosures and discovery.	Commencement of the evidence-gathering phase.
2017-05-05	Magistrate Judge John F. Toohey III issues a scheduling order.	Establishes deadlines for discovery, motions, and other case milestones.
2017-08-15	Pfizer files a motion for preliminary injunction.	Seeks to prevent Zydus from launching its generic product pending the outcome of the litigation.
2017-09-05	Zydus files an opposition to Pfizer's motion for preliminary injunction.	Zydus argues against the injunction, asserting it would cause irreparable harm to its business.
2017-10-11	Magistrate Judge Toohey recommends denying Pfizer's motion for preliminary injunction.	Initial setback for Pfizer's immediate injunctive relief efforts.
2017-10-25	District Judge Gregory J. Porambo adopts the magistrate judge's recommendation and denies Pfizer's motion for preliminary injunction.	Confirms the denial of preliminary injunction, allowing Zydus to continue with its ANDA process subject to other factors.
2017-12-15	Parties file joint proposed claim constructions for U.S. Patent No. 8,110,204.	Start of the claim construction phase, crucial for determining the scope of patent protection.
2018-01-12	District Judge Porambo issues a Memorandum and Order on Claim Construction for U.S. Patent No. 8,110,204.	Defines the meaning of key terms in the asserted claims, impacting infringement analysis.
2018-03-09	Parties file joint proposed claim constructions for U.S. Patent No. 9,175,014.	Continuation of the claim construction process for the second asserted patent.
2018-04-20	District Judge Porambo issues a Memorandum and Order on Claim Construction for U.S. Patent No. 9,175,014.	Finalizes claim constructions for both asserted patents.
2018-07-13	Zydus files a motion for summary judgment of non-infringement.	Zydus seeks dismissal of infringement claims based on the established claim constructions.
2018-08-10	Pfizer files an opposition to Zydus's motion for summary judgment.	Pfizer argues that genuine disputes of material fact preclude summary judgment.
2018-09-14	Zydus files a reply in further support of its motion for summary judgment.	Reinforces Zydus's arguments for dismissal.
2018-10-02	District Judge Porambo issues a Memorandum and Order denying Zydus's motion for summary judgment of non-infringement.	Denies immediate dismissal, indicating that infringement issues require further adjudication.
2018-10-12	Zydus files a motion for summary judgment of invalidity.	Zydus directly challenges the patentability of Pfizer's asserted patents.
2018-11-09	Pfizer files an opposition to Zydus's motion for summary judgment of invalidity.	Pfizer defends the validity of its patents against Zydus's claims.
2018-12-17	District Judge Porambo issues a Memorandum and Order denying Zydus's motion for summary judgment of invalidity.	Denies dismissal on invalidity grounds, confirming that these issues will proceed.
2019-01-18	Pfizer files a motion for summary judgment of infringement.	Pfizer seeks a ruling that Zydus's ANDA infringes the asserted patents.
2019-02-19	Zydus files an opposition to Pfizer's motion for summary judgment of infringement.	Zydus opposes summary judgment, arguing material facts are in dispute.
2019-03-22	District Judge Porambo issues a Memorandum and Order denying Pfizer's motion for summary judgment of infringement.	Denies immediate infringement ruling, necessitating further proceedings.
2019-04-05	Zydus files a motion for reconsideration of the Court's order denying its motion for summary judgment of invalidity.	Zydus seeks to re-open the invalidity question based on specific arguments.
2019-04-19	Pfizer files an opposition to Zydus's motion for reconsideration.	Pfizer argues against reconsideration.
2019-05-13	District Judge Porambo issues a Memorandum and Order denying Zydus's motion for reconsideration.	Upholds the prior decision denying summary judgment of invalidity.
2019-06-10	Zydus files a motion for leave to file an interlocutory appeal regarding the denial of summary judgment of invalidity.	Zydus seeks permission to appeal the denial of invalidity summary judgment to a higher court.
2019-07-15	District Judge Porambo issues a Memorandum and Order denying Zydus's motion for leave to file an interlocutory appeal.	Denies Zydus's request for interlocutory appeal, meaning the case will continue in the district court.
2019-08-16	The U.S. Court of Appeals for the Federal Circuit issues a Mandate following Zydus's appeal of the denial of its motion for reconsideration.	This indicates a procedural step related to Zydus's prior appeals or filings with the Federal Circuit.
2020-02-06	District Judge Kimberly J. Mueller is assigned to the case.	Change in judicial assignment.
2020-03-11	Magistrate Judge Katherine M. Smith issues a Report and Recommendation on Zydus's motion to dismiss or stay pending IPRs.	Addresses Zydus's attempts to utilize Inter Partes Review (IPR) proceedings as grounds for dismissal or stay.
2020-03-24	District Judge Mueller adopts the Report and Recommendation, denying Zydus's motion to dismiss or stay.	Upholds the continuation of the district court litigation despite IPR proceedings.
2020-04-16	Zydus files a notice of appeal to the U.S. Court of Appeals for the Federal Circuit.	Zydus appeals earlier district court rulings.
2020-07-17	The U.S. Court of Appeals for the Federal Circuit issues an opinion, affirming in part and vacating in part the district court's judgment.	This is a significant appellate ruling that could alter the course of the litigation.
2020-08-17	Zydus files a petition for panel rehearing or rehearing en banc.	Zydus seeks further review by the Federal Circuit.
2020-09-10	The U.S. Court of Appeals for the Federal Circuit denies Zydus's petition for rehearing.	The Federal Circuit's previous decision stands.
2021-01-19	The U.S. Supreme Court denies Zydus's petition for a writ of certiorari.	Zydus's attempt to appeal to the Supreme Court is unsuccessful. The Federal Circuit's mandate becomes final.
2021-02-23	District Judge Mueller issues an Order of Remand, sending the case back to the District Court for further proceedings consistent with the Federal Circuit's mandate.	The litigation resumes in the district court following the appellate process.
2021-03-19	Zydus files a Second Amended Answer and Counterclaim.	Updates Zydus's defenses and claims in light of previous court rulings and developments.
2021-04-12	Pfizer files a Motion to Dismiss Zydus's Second Amended Counterclaims.	Pfizer seeks to strike or dismiss certain claims raised by Zydus.
2021-05-24	District Judge Mueller issues an Order granting in part and denying in part Pfizer's Motion to Dismiss Zydus's Second Amended Counterclaims.	Resolves specific counterclaims filed by Zydus, narrowing the issues.
2021-06-15	Zydus files an Answer to Pfizer's Complaint.	Zydus formally responds to Pfizer's allegations.
2021-07-29	District Judge Mueller issues an Order regarding Zydus's Motion for Protective Order, which is granted in part and denied in part.	Addresses discovery disputes and protective measures.
2022-02-15	District Judge Mueller issues an Order denying Zydus's Motion for Summary Judgment of Non-Infringement.	Reaffirms that infringement remains a disputed issue for trial.
2022-02-28	District Judge Mueller issues an Order denying Zydus's Motion for Summary Judgment of Invalidity.	Reaffirms that invalidity remains a disputed issue for trial.
2022-03-14	District Judge Mueller issues an Order regarding the Final Pretrial Conference.	Prepares the case for trial, setting the final procedural steps.
2022-03-23	Zydus Pharmaceuticals (USA) Inc. files a Notice of Appeal to the U.S. Court of Appeals for the Federal Circuit.	Zydus appeals the District Court's denial of summary judgment of non-infringement and invalidity.
2022-07-01	The U.S. Court of Appeals for the Federal Circuit issues an Opinion affirming the District Court's denial of Zydus's Motion for Summary Judgment of Non-Infringement.	Appellate court upholds the district court's decision, meaning infringement remains a jury question.
2022-07-01	The U.S. Court of Appeals for the Federal Circuit issues an Opinion affirming the District Court's denial of Zydus's Motion for Summary Judgment of Invalidity.	Appellate court upholds the district court's decision, meaning invalidity remains a jury question.
2022-08-22	Zydus Pharmaceuticals (USA) Inc. files a Petition for Panel Rehearing or Rehearing En Banc.	Zydus seeks further review from the Federal Circuit.
2022-09-15	The U.S. Court of Appeals for the Federal Circuit denies Zydus's Petition for Panel Rehearing or Rehearing En Banc.	The Federal Circuit's July 1, 2022, decisions are finalized.
2022-11-10	The U.S. Supreme Court denies Zydus's Petition for a Writ of Certiorari.	Zydus's final attempt to appeal to the Supreme Court fails, making the Federal Circuit's decisions the final word in this appellate phase.

Court Decisions and Interpretations

The litigation has involved several key rulings on claim construction, summary judgment, and appeals.

Claim Construction

District Judge Porambo issued claim construction orders for both asserted patents. These interpretations are critical as they define the scope of Pfizer's patent rights and how a competitor's product may infringe.

• U.S. Patent No. 8,110,204: The court construed claims related to methods of treating rheumatoid arthritis. The specific constructions would dictate whether Zydus's proposed generic product, when used as directed, falls within the patented method.
• U.S. Patent No. 9,175,014: The court interpreted claims related to tofacitinib citrate compounds. This construction influences whether Zydus's generic drug contains a compound that infringes Pfizer's patent.

These claim construction rulings were foundational for subsequent summary judgment motions, as the interpretation of patent claims directly impacts whether infringement or invalidity can be determined as a matter of law.

Summary Judgment Rulings

The case has seen multiple motions for summary judgment from both parties:

• Zydus's Motions for Summary Judgment of Non-Infringement and Invalidity: Zydus repeatedly sought to have the case dismissed before trial, arguing that Pfizer's patents were invalid or that its generic product could not infringe. These motions were consistently denied by the District Court. The court found that genuine disputes of material fact existed regarding both infringement and validity, necessitating a trial.
• Pfizer's Motion for Summary Judgment of Infringement: Pfizer also sought a pre-trial ruling that Zydus's product infringed. This motion was also denied, as the court determined that factual issues remained regarding whether Zydus's ANDA would induce infringement.

Federal Circuit Appeals

Zydus pursued appeals of the district court's denials of summary judgment. The U.S. Court of Appeals for the Federal Circuit played a pivotal role in shaping the litigation's trajectory.

• In its July 1, 2022, opinions, the Federal Circuit affirmed the District Court's denial of Zydus's motions for summary judgment of both non-infringement and invalidity. This outcome means that the questions of whether Zydus infringes Pfizer's patents and whether those patents are valid remain for further adjudication, likely by a jury. The appellate court found that substantial factual disputes precluded judgment as a matter of law on these issues.
• Zydus's subsequent petitions for rehearing and the U.S. Supreme Court's denial of certiorari effectively finalized the Federal Circuit's rulings, leaving the case poised for further district court proceedings on the merits of infringement and validity.

Market Implications and Strategic Considerations

This litigation has direct implications for the market entry of generic tofacitinib citrate. Xeljanz generated approximately $2.7 billion in revenue for Pfizer in 2022 [1], making its patent protection a significant financial interest.

• Generic Entry Timing: The success or failure of Zydus's ANDA approval and subsequent launch is directly tied to the outcome of this patent litigation. A favorable ruling for Zydus, or a successful invalidation of Pfizer's patents, could accelerate generic competition, leading to significant price erosion for Xeljanz. Conversely, if Pfizer prevails on infringement and the patents are upheld, Zydus's generic launch would be blocked, preserving Xeljanz's market exclusivity for the duration of the patents' remaining terms.
• Patent Landscape: The ongoing litigation highlights the strategic importance of patents in the pharmaceutical industry. Pfizer's use of multiple patents and its vigorous defense underscore the effort required to protect blockbuster drugs from generic competition.
• Litigation Costs: The extended duration and complexity of this case, involving multiple rounds of appeals and extensive motion practice, represent substantial legal costs for both parties. These costs are a factor in any R&D or investment decision.
• ANDA Strategy: Zydus's actions demonstrate a common strategy for generic manufacturers: challenging the validity and/or non-infringement of innovator patents as a pathway to market entry. The outcomes here provide insights into the potential success of such strategies against established patents.

Key Takeaways

• Pfizer's patents U.S. Patent Nos. 8,110,204 and 9,175,014 are the subject of infringement allegations by Zydus Pharmaceuticals (USA) Inc. concerning Zydus's generic tofacitinib citrate product.
• The litigation has progressed through claim construction, multiple summary judgment motions, and appeals to the U.S. Court of Appeals for the Federal Circuit.
• The Federal Circuit affirmed the District Court's denial of Zydus's motions for summary judgment of non-infringement and invalidity, indicating that these critical issues require further adjudication.
• The case's progression suggests that a trial on the merits of infringement and patent validity is likely, absent a settlement.
• The outcome of this litigation will directly impact the availability and pricing of generic tofacitinib citrate in the U.S. market.

Frequently Asked Questions

1. What is the primary dispute in Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc.? The core dispute is whether Zydus's proposed generic version of Pfizer's drug Xeljanz (tofacitinib citrate) infringes upon Pfizer's U.S. Patent Nos. 8,110,204 and 9,175,014. Zydus is also challenging the validity of these patents.

2. What was the outcome of the recent appeals to the U.S. Court of Appeals for the Federal Circuit? The Federal Circuit affirmed the District Court's decisions to deny Zydus's motions for summary judgment of both non-infringement and invalidity. This means that the issues of infringement and patent validity will proceed further in the litigation.

3. When can Zydus Pharmaceuticals launch its generic tofacitinib citrate product? Zydus cannot launch its product if it infringes Pfizer's valid patents. The ongoing litigation means that the launch is contingent on the final resolution of these patent disputes. The Federal Circuit's rulings suggest the case is not yet resolved in Zydus's favor.

4. What is the significance of the claim construction rulings in this case? Claim construction defines the scope of patent rights. The District Court's interpretations of Pfizer's patent claims are critical because they determine what constitutes infringement. These constructions set the stage for evaluating whether Zydus's generic product falls within the protected claims.

5. Has the U.S. Supreme Court taken any action in this case? The U.S. Supreme Court denied Zydus's petition for a writ of certiorari, meaning the Supreme Court declined to hear the case. This denial leaves the decisions of the U.S. Court of Appeals for the Federal Circuit as the final word on the appellate matters reviewed.

Citations

[1] Pfizer Inc. (2023). Pfizer Reports Fourth Quarter and Full-Year 2022 Results. [Press release]. Retrieved from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-fourth-quarter-and-full-year-2022-results